Senseonics, Inc.

Senseonics, Inc. is a publicly traded medical device company headquartered in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company manufactures and markets the Eversense system, the first and only long-term implantable continuous glucose monitoring device. The Eversense CGM system features a subcutaneous glucose sensor designed for extended wear periods, including a 180-day implantable version and a next-generation 365-day implantable variant. The company's products are distributed through partnerships, including Ascensia Diabetes Care for select markets. Senseonics supports its systems with clinical evidence demonstrating improved glycemic control in CGM-naive patients, validated through clinical studies including the PROMISE and ENHANCE trials. The company maintains robust regulatory compliance with FDA clearance for its implantable glucose monitoring technology. Senseonics serves endocrinologists, diabetes educators, and hospital-based diabetes management programs across the United States and international markets, positioning itself as a leader in long-acting implantable CGM technology differentiated from traditional wearable glucose monitoring alternatives.